Considerations for Second-Line Treatment Decisions in EGFR+ NSCLC: Sequencing Strategies and First-Line Choices

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.